d1,s4a,s5-analytical methods for nitrosamines in pharmaceuticals: progress, pitfalls and prospects
Published 2 years ago • 425 plays • Length 13:01
Download video MP4
Download video MP3
Similar videos
-
14:26
d1,s4a,s4-data gaps & evolving areas in controlling nitrosamine formation: drug products & apis
-
10:38
d1,s4a,s3-exploration of forward-looking ideas for inhibiting nitrosamine formation in drug products
-
11:25
d1,s4a,s6-safety & risk assessment of excipient contributions to nitrosamine formation
-
4:56
d1,s3,s3-understanding endogenous nitrosation -vs- impact of nitrosamine impurities in drug products
-
10:49
d1,s4b,s1-characterization of excipients in complex dosage forms – fda research & goals
-
5:08
d1,s4a,s1-session introduction
-
52:05
analytical solutions for the accurate determination of nitrosamines produced in the manufacture of..
-
44:52
nitrosamine impurities-aug 2023 ndsris limit usfda guidance | control of nitrosamine guidance feb-21
-
0:32
how to be medicinewise- lesson 4 - what are the side effects?
-
23:53
nitrosamines: where are we now?
-
2:11
nitrosamines risk assessment - view from an expert
-
0:58
data-driven methods to detect diagnostic errors in clinical data
-
3:29
understanding prescription medicines — diabetes, medicines and me series
-
24:34
dose-scale analysis in pharmacodynamic equivalence (31of35) complex generics – sep. 25-26, 2019
-
7:30
generics and biosimilars
Clip.africa.com - Privacy-policy